Category: Cancer Pharmacology
-
What Does It Mean By FDA Accelerated Approval Of Cancer Drugs?
A new cancer drug can reach patients before its expected benefit has been fully verified. Here is what FDA accelerated approval means, why confirmatory trials matter, and what patients can ask.
-
From Failed Experiments to FDA Approval
A simple look at how years of failed experiments, patient participation, and persistent cancer pharmacology helped turn a difficult target into an approved medicine.
-
DFMO: The Pill Designed to Help Keep High-Risk Neuroblastoma From Coming Back
In December 2023, the FDA approved eflornithine, also called DFMO or Iwilfin, to help reduce the risk that high-risk neuroblastoma comes back after intensive treatment. The science centers on polyamines, small molecules that some MYCN-driven tumors rely on to keep growing.
-
Can weight-loss drugs lower cancer risk? What the GLP-1 boom is really telling us
Written and edited by Abel B. Daartey, PharmD Key Takeaways GLP-1 drugs may lower cancer risk indirectly by helping some people lose substantial weight and improve metabolic health. The evidence for cancer is promising, but much of it is observational, so it cannot yet prove that GLP-1 medicines prevent cancer. These medicines should be used…
-
Why Are More Young People Getting Colon Cancer?
Early-onset colorectal cancer is rising in adults younger than 50. The causes are probably mixed: diet, metabolism, gut bacteria, alcohol, sedentary life, early-life exposures, and delayed recognition of symptoms.
-
Catch It Early: The Science and Limits of Cancer Screening
Cancer screening saves lives when used for the right cancers and the right people. But it also has limits, including false positives, overdiagnosis, and the need for careful follow-up.
